98%
921
2 minutes
20
Heart failure (HF) is a complex clinical syndrome characterized by the heart's reduced capacity to meet the body's circulatory demands, frequently complicated by fluid overload. This accumulation of fluid contributes significantly to symptoms such as dyspnea, peripheral edema, and fatigue, and is driven by neurohormonal dysregulation involving the renin-angiotensin-aldosterone system and sympathetic nervous system. Fluid restriction has long been a cornerstone of HF management, intended to mitigate volume overload, improve symptoms, and prevent hospital readmissions. However, recent studies, including the FRESH-UP (Fluid REStriction in Heart failure vs Liberal Fluid UPtake) trial, suggest that strict fluid limitation may not yield substantial clinical benefits in stable HF patients and may negatively impact quality of life due to increased thirst and discomfort. Current guidelines recommend fluid restriction selectively, particularly for those with persistent congestion or hyponatremia unresponsive to standard therapy. Emerging evidence favors a more individualized approach to fluid management, considering patient-specific factors such as functional class, ejection fraction, symptom burden, and treatment response. Ongoing research is needed to refine these strategies, optimize patient outcomes, and enhance quality of life through more tailored fluid management protocols in HF care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CRD.0000000000001007 | DOI Listing |
J Endocrinol Invest
September 2025
Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Exercise associated hyponatremia (EAH) is a medical condition that can occur during physical exertion. Initially, EAH was considered to be restricted to extreme endurance activities, such as ultramarathons and Ironman triathlons. However, it has been more recently recognized in a variety of sports, including team sports and in shorter-duration events.
View Article and Find Full Text PDFEur J Neurol
September 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Background: No standardized strategy for integrating κ-free light chain (κ-FLC) index into routine cerebrospinal fluid (CSF) diagnostics has yet been established.
Objective: To determine agreement between κ-FLC index and CSF-restricted oligoclonal bands (OCB), and to identify κ-FLC index range where second-line OCB testing is needed.
Methods: A retrospective analysis was conducted in patients who had κ-FLC measurement between December 2023 and December 2024 at the Medical University of Innsbruck.
Nat Commun
September 2025
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
The distribution of tau pathology in Alzheimer's disease (AD) shows remarkable inter-individual heterogeneity, including hemispheric asymmetry. However, the factors driving this asymmetry remain poorly understood. Here we explore whether tau asymmetry is linked to i) reduced inter-hemispheric brain connectivity (potentially restricting tau spread), or ii) asymmetry in amyloid-beta (Aβ) distribution (indicating greater hemisphere-specific vulnerability to AD pathology).
View Article and Find Full Text PDFPediatr Pulmonol
September 2025
Department of Neonatology, La Paz University Hospital, Madrid, Spain.
Objective: To describe national patterns in the screening, diagnosis, and clinical management of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) in Spanish neonatal intensive care units (NICUs) and assess the need for standardized screening and management protocols and unified follow-up strategies.
Methods: A 20-question electronic survey was distributed to all Level III NICUs in the Spanish public health system to evaluate practices in BPD-PH screening, diagnosis, and clinical management. Results were analyzed globally and by NICU level (IIIB vs.
Eur Heart J Case Rep
September 2025
Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, 11 Robin Warren Drive, Murdoch, WA 6150, Australia.
Background: Diagnosing the cause of undifferentiated left ventricular hypertrophy (LVH) in a patient with progressive heart failure symptoms can present a diagnostic challenge, with potential for both inherited and acquired aetiologies. Hydroxychloroquine-induced cardiomyopathy (HCQ-CM) is a rare complication of long-term hydroxychloroquine use. This case report highlights its clinical presentation, key differential diagnoses, and treatment strategies.
View Article and Find Full Text PDF